JAB-3068
- Generic Name
- JAB-3068
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26F2N6O2S
- CAS Number
- -
- Unique Ingredient Identifier
- V6Q7413SA8
- Associated Conditions
- -
- Associated Therapies
- -
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT04721223
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT03565003
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT03518554
- Locations
- 🇺🇸
HealthONE Clinic Services Oncology-Hematology, Denver, Colorado, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath